Skip to main content
SpringerLink
Log in

Corticosteroids

  • Chapter
  • First Online:
Neurorheumatology

Abstract

In this chapter, we discuss important concepts that are useful to the neurologist using corticosteroids in disease management. Corticosteroids are one of the most common medications used to treat many inflammatory, autoimmune, and allergic conditions. Corticosteroids have genomic and non-genomic effects on cells. The two main genomic effects of corticosteroids are transactivation and transrepression. Many of the side effects of corticosteroids are mediated via transactivation, while the beneficial anti-inflammatory effects are mediated via transrepression. Low-dose corticosteroids are used as maintenance therapy for chronic autoimmune and inflammatory conditions. Higher doses of corticosteroids (including pulse therapy for organ- or life-threatening disease) are used for initial treatment and are tapered once the disease process is controlled. Major side effects of corticosteroids include lipodystrophy, weight gain, metabolic disorders, neuropsychiatric alterations, glucocorticoid-induced osteoporosis, increased infection risk, cataracts, and skin atrophy. The dose and duration of corticosteroids should be minimized to reduce the occurrence of these side effects. Optimizing therapeutic response and steps to minimize side effects are discussed in the text of this chapter.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 159.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Burns CM. The history of cortisone discovery and development. Rheum Dis Clin N Am. 2016 Feb;42(1):1–14. vii.

    Article  Google Scholar 

  2. Schacke H, Docke WD, Asadullah K. Mechanisms involved in the side effects of glucocorticoids. Pharmacol Ther. 2002;96(1):23–43.

    Article  CAS  Google Scholar 

  3. Stahn C, Buttgereit F. Genomic and nongenomic effects of glucocorticoids. Nat Clin Pract Rheumatol. 2008;4(10):525–33.

    Article  CAS  Google Scholar 

  4. De Bosscher K, Van Craenenbroeck K, Meijer OC, Haegeman G. Selective transrepression versus transactivation mechanisms by glucocorticoid receptor modulators in stress and immune systems. Eur J Pharmacol. 2008;583(2–3):290–302.

    Article  Google Scholar 

  5. Newton R. Molecular mechanisms of glucocorticoid action: what is important? Thorax. 2000 Jul;55(7):603–13.

    Article  CAS  Google Scholar 

  6. Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, et al. Dissociation of transactivation from transrepression by a selective glucocorticoid receptor agonist leads to separation of therapeutic effects from side effects. Proc Natl Acad Sci U S A. 2004;101(1):227–32.

    Article  Google Scholar 

  7. Buttgereit F, Brand MD, Burmester GR. Equivalent doses and relative drug potencies for non-genomic glucocorticoid effects: a novel glucocorticoid hierarchy. Biochem Pharmacol. 1999;58(2):363–8.

    Article  CAS  Google Scholar 

  8. Buttgereit F, da Silva JA, Boers M, Burmester GR, Cutolo M, Jacobs J, et al. Standardised nomenclature for glucocorticoid dosages and glucocorticoid treatment regimens: current questions and tentative answers in rheumatology. Ann Rheum Dis. 2002;61(8):718–22.

    Article  CAS  Google Scholar 

  9. Duru N, van der Goes MC, Jacobs JW, Andrews T, Boers M, Buttgereit F, et al. Eular evidence-based and consensus-based recommendations on the management of medium to high-dose glucocorticoid therapy in rheumatic diseases. Ann Rheum Dis. 2013;72(12):1905–13.

    Article  CAS  Google Scholar 

  10. Buttgereit F, Straub RH, Wehling M, Burmester GR. Glucocorticoids in the treatment of rheumatic diseases: an update on the mechanisms of action. Arthritis Rheum. 2004;50(11):3408–17.

    Article  CAS  Google Scholar 

  11. Fardet L, Flahault A, Kettaneh A, Tiev KP, Genereau T, Toledano C, et al. Corticosteroid-induced clinical adverse events: frequency, risk factors and patient’s opinion. Br J Dermatol. 2007;157(1):142–8.

    Article  CAS  Google Scholar 

  12. Curtis JR, Westfall AO, Allison J, Bijlsma JW, Freeman A, George V, et al. Population-based assessment of adverse events associated with long-term glucocorticoid use. Arthritis Rheum. 2006;55(3):420–6.

    Article  Google Scholar 

  13. Liu D, Ahmet A, Ward L, Krishnamoorthy P, Mandelcorn ED, Leigh R, et al. A practical guide to the monitoring and management of the complications of systemic corticosteroid therapy. Allergy Asthma Clin Immunol. 2013;9(1):30.

    Article  Google Scholar 

  14. Judd LL, Schettler PJ, Brown ES, Wolkowitz OM, Sternberg EM, Bender BG, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014;171(10):1045–51.

    Article  Google Scholar 

  15. Lanza FL, Chan FK, Quigley EM. Practice parameters Committee of the American College of G. guidelines for prevention of nsaid-related ulcer complications. Am J Gastroenterol. 2009;104(3):728–38.

    Article  Google Scholar 

  16. Youssef J, Novosad SA, Winthrop KL. Infection risk and safety of corticosteroid use. Rheum Dis Clin N Am. 2016;42(1):157–76. ix–x.

    Article  Google Scholar 

  17. Centers for Disease Control and Prevention. Recommended adult immunization schedule-United States. 2015 [cited 2016 October 5]; Available from: http://www.cdc.gov/vaccines/schedules/hcp/adult.html

  18. Center for Disease Control and Prevention. Shingles (herpes zoster). 2014 [cited 2016 October 5]; Available from: https://www.cdc.gov/shingles/vaccination.html

  19. Yale SH, Limper AH. Pneumocystis carinii pneumonia in patients without acquired immunodeficiency syndrome: associated illness and prior corticosteroid therapy. Mayo Clin Proc. 1996;71(1):5–13.

    Article  CAS  Google Scholar 

  20. Anonymous. Targeted tuberculin testing and treatment of latent tuberculosis infection. American thoracic society. MMWR Recomm Reps. 2000;49(RR-6):1–51.

    Google Scholar 

  21. Buckley L, Guyatt G, Fink HA et al., 2017 American College of Rheumatology guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthr Rheum, 2017; 69: 1521–37.

    Article  Google Scholar 

  22. Berthon BS, MacDonald-Wicks LK, Wood LG. A systematic review of the effect of oral glucocorticoids on energy intake, appetite, and body weight in humans. Nutr Res. 2014;34(3):179–90.

    Article  CAS  Google Scholar 

  23. Schoepe S, Schacke H, May E, Asadullah K. Glucocorticoid therapy-induced skin atrophy. Exp Dermatol. 2006;15(6):406–20.

    Article  CAS  Google Scholar 

  24. Fardet L, Petersen I, Nazareth I. Suicidal behavior and severe neuropsychiatric disorders following glucocorticoid therapy in primary care. Am J Psychiatry. 2012;169(5):491–7.

    Article  Google Scholar 

  25. Fardet L, Petersen I, Nazareth I. Prevalence of long-term oral glucocorticoid prescriptions in the Uk over the past 20 years. Rheumatology. 2011;50(11):1982–90.

    Article  Google Scholar 

  26. Canalis E, Mazziotti G, Giustina A, Bilezikian JP. Glucocorticoid-induced osteoporosis: pathophysiology and therapy. Osteoporos Int. 2007;18(10):1319–28.

    Article  CAS  Google Scholar 

  27. Rizzoli R, Biver E. Glucocorticoid-induced osteoporosis: who to treat with what agent? Nat Rev Rheumatol. 2015;11(2):98–109.

    Article  CAS  Google Scholar 

  28. Natsui K, Tanaka K, Suda M, Yasoda A, Sakuma Y, Ozasa A, et al. High-dose glucocorticoid treatment induces rapid loss of trabecular bone mineral density and lean body mass. Osteoporos Int. 2006;17(1):105–8.

    Article  CAS  Google Scholar 

  29. Van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Use of oral corticosteroids and risk of fractures. J Bone Miner Res Off J Am Soc Bone Miner Res 2000;15(6):993–1000.

    Article  CAS  Google Scholar 

  30. Ramsey-Goldman R, Dunn JE, Huang CF, Dunlop D, Rairie JE, Fitzgerald S, et al. Frequency of fractures in women with systemic lupus erythematosus: comparison with United States population data. Arthritis Rheum. 1999;42(5):882–90.

    Article  CAS  Google Scholar 

  31. van Staa TP, Leufkens HG, Abenhaim L, Zhang B, Cooper C. Oral corticosteroids and fracture risk: relationship to daily and cumulative doses. Rheumatology. 2000;39(12):1383–9.

    Article  Google Scholar 

  32. Buehring B, Viswanathan R, Binkley N, Busse W. Glucocorticoid-induced osteoporosis: an update on effects and management. J Allergy Clin Immunol. 2013;132(5):1019–30.

    Article  CAS  Google Scholar 

  33. Whittier X, Saag KG. Glucocorticoid-induced osteoporosis. Rheum Dis Clin N Am. 2016;42(1):177–89. x.

    Article  Google Scholar 

  34. Lekamwasam S, Adachi JD, Agnusdei D, Bilezikian J, Boonen S, Borgstrom F, et al. A framework for the development of guidelines for the management of glucocorticoid-induced osteoporosis. Osteoporos Int. 2012;23(9):2257–76.

    Article  CAS  Google Scholar 

  35. Van Staa TP, Laan RF, Barton IP, Cohen S, Reid DM, Cooper C. Bone density threshold and other predictors of vertebral fracture in patients receiving oral glucocorticoid therapy. Arthritis Rheum. 2003;48(11):3224–9.

    Article  Google Scholar 

  36. Saag KG, Zanchetta JR, Devogelaer JP, Adler RA, Eastell R, See K, et al. Effects of teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: thirty-six-month results of a randomized, double-blind, controlled trial. Arthritis Rheum. 2009;60(11):3346–55.

    Article  CAS  Google Scholar 

  37. Powell C, Chang C, Naguwa SM, Cheema G, Gershwin ME. Steroid induced osteonecrosis: an analysis of steroid dosing risk. Autoimmunity reviews. Review. 2010;9(11):721–43.

    CAS  Google Scholar 

  38. Franchimont D. Overview of the actions of glucocorticoids on the immune response: a good model to characterize new pathways of immunosuppression for new treatment strategies. Ann N Y Acad Sci. 2004;1024:124–37.

    Article  CAS  Google Scholar 

  39. Stuck AE, Minder CE, Frey FJ. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis. 1989;11(6):954–63.

    Article  CAS  Google Scholar 

  40. Cutolo M, Seriolo B, Pizzorni C, Secchi ME, Soldano S, Paolino S, et al. Use of glucocorticoids and risk of infections. Autoimmun Rev. 2008;8(2):153–5.

    Article  CAS  Google Scholar 

  41. Jones R 3rd, Rhee DJ. Corticosteroid-induced ocular hypertension and glaucoma: a brief review and update of the literature. Curr Opin Ophthalmol. 2006;17(2):163–7.

    PubMed  Google Scholar 

  42. Piper JM, Ray WA, Daugherty JR, Griffin MR. Corticosteroid use and peptic ulcer disease: role of nonsteroidal anti-inflammatory drugs. Ann Intern Med. 1991;114(9):735–40.

    Article  CAS  Google Scholar 

  43. Wei L, MacDonald TM, Walker BR. Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med. 2004;141(10):764–70.

    Article  Google Scholar 

  44. Souverein PC, Berard A, Van Staa TP, Cooper C, Egberts AC, Leufkens HG, et al. Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart. 2004;90(8):859–65.

    Article  CAS  Google Scholar 

  45. Maradit Kremers H, Reinalda MS, Crowson CS, Davis JM 3rd, Hunder GG, Gabriel SE. Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum. 2007;57(2):279–86.

    Article  Google Scholar 

  46. Buttgereit F, Burmester GR, Lipworth BJ. Inflammation, glucocorticoids and risk of cardiovascular disease. Nat Clin Pract Rheumatol. 2009;5(1):18–9.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Rheumatology, Bone and Joint Center, Straub Medical Center, Honolulu, HI, USA

    Sian Yik Lim

  2. Rheumatology Fellowship Training Program, Department of Rheumatology, Massachusetts General Hospital, Boston, MA, USA

    Marcy B. Bolster

Authors
  1. Sian Yik Lim
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Marcy B. Bolster
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Marcy B. Bolster .

Editor information

Editors and Affiliations

  1. Division of Neuroimmunology, University of Iowa, Iowa City, IA, USA

    Tracey A. Cho

  2. Department of Neurology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Shamik Bhattacharyya

  3. Division of Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, USA

    Simon Helfgott

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Lim, S.Y., Bolster, M.B. (2019). Corticosteroids. In: Cho, T., Bhattacharyya, S., Helfgott, S. (eds) Neurorheumatology. Springer, Cham. https://doi.org/10.1007/978-3-030-16928-2_28

Download citation

  • DOI: https://doi.org/10.1007/978-3-030-16928-2_28

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-030-16927-5

  • Online ISBN: 978-3-030-16928-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation